Business
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast on Tuesday,
About this update from Supernus Pharmaceuticals, Inc.
[{"type":"image","alt":"Supernus Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Supernus Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/e106c72a48ff432ec8d84873fc8164bb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1cawVaerzPmjsZf0nQ1wUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNg--/https://media.zenfs.com/en/globenewswire.com/e106c72a48ff432ec8d84873fc8164bb","width":300,"height":76}},"lazy":false},{"type":"text","content":"ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026.","length":371,"tagName":"p"},{"type":"text","content":"Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET to discuss these results. Following management’s prepared remarks and discussion of business results, the call will be open for questions.","length":296,"tagName":"p"},{"type":"text","content":"A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/Investors.","length":150,"tagName":"p"},{"type":"text","content":"Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.","length":251,"tagName":"p"},{"type":"text","content":"Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/Investors. The webcast will be available on the Company’s website for 60 days following the live call.","length":222,"tagName":"p"},{"type":"text","content":"About Supernus Pharmaceuticals, Inc. ","length":36,"tagName":"p"},{"type":"text","content":"Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases....